Category Archives: Cf

In this week's episode, Anthony Fenech looks at the Joe Jimenez, Anibal Sanchez dilemma, and talks Cleveland Indians with Zack Meisel of cleveland.com on April 14, 2017. Subscribe to "Talkin' Tigers" in iTunes or Google.

Tigers shortstop Jose Iglesias throws out Indians catcher Roberto Perez at first base during the seventh inning Friday in Cleveland.(Photo: Tony Dejak, AP)

When: 4:10 p.m.

Where: Progressive Field, Cleveland.

TV: Fox Sports Detroit, Fox Sports 1.

Radio: WXYT-FM (97.1; other radio affiliates).

Weather forecast: Mostly cloudy, 75 degrees, 5%-10% chance of rain.

Probable starting pitchers: RHP Justin Verlander (1-0, 1.35 ERA) vs. RHP Corey Kluber (0-1, 5.25 ERA).

Tigers lineup:

1. Ian Kinsler, 2B 2. Nick Castellanos, 3B 3. Miguel Cabrera, 1B 4. Victor Martinez, DH 5. Justin Upton, LF 6. Tyler Collins, RF 7. James McCann, C 8. Andrew Romine, CF 9. Jose Iglesias, SS

Game notes: Last season, the Tigers lost the first 11 games against the Indians. But in Game 1 of their first series of 2017, the Tigers drew first blood. Though it was nearly too bloody. Home runs from Miguel Cabrera and Alex Avila and a solid six innings from Daniel Norris were nearly spoiled by the bullpen. But Detroit came away with a 7-6 win. Today, on national TV, the teams' aces take the mound in Verlander and Kluber.

Related:

Detroit Tigers add Warwick Saupold to help beleaguered bullpen

Miguel Cabrera's beef was with Indians' Terry Francona Friday, not Bauer

Toledo coaches aim to get Bruce Rondon 'back on track'

Twitter updates

On mobile? Tap here for live updates.

Continued here:

Game thread: Verlander gives up 3-run HR; Tigers down 3-0 to Indians - Detroit Free Press

WHAT IT MEANS:

Rock CF funds life changing research initiatives, and using fitness, the arts, entertainment, and fashion to heighten awareness to ultimately improve the quality of life for patients living with cystic fibrosis.Emily Schaller, who founded Rock CF and is thriving with CF, is committed to rocking CF so hard that CF will one day stand for cure found.Rock CF empowers CF patients to take ownership of their health, inspire exercise as a form of treatment and fight each day with a positive approach.

Emily from Rock CF discovered BowTie cause after seeing Ken Rosenthal wear the ties on air, it was history from there!

Rock CFs message and logos are empowering to CF patients and supporters worldwide, putting the Rock in rock the bowtie!

HOW TO GET INVOLVED:

Website: http://www.letsrockcf.org

Facebook: http://www.facebook.com/letsrockcf

Twitter: http://www.twitter.com/LetsRrockCf

FOX Fantasy Baseball Join or Create a Free League

Read the original post:

This week's bowtie represents ... Rock CF Foundation - FOXSports.com

Three more Texas players will miss the spring game because of injuries.

Herman doesnt mince any words when it comes to a players performance.

When we leave spring practice youll have kind of a definitive pecking order of guys that we trust, guys that are on the cusp, guys that are probably a year away and the guys thatll never be there, Herman said. Youve had 15 practices to prove what kind of football player you are to us.

Special teams coach Craig Naivar could be the difference between a sputter and a revival.

There could be big changes coming for recruiting.

A proposal to alter the recruiting calendar and to add a 10th full-time assistant coach, among other things, will be heard by the Division 1 Council. If the Division 1 Council approves, the NCAA Board of Directors can finalize the rule alterations two weeks later. If these changes are indeed enacted, the way programs recruit both with their assistant coaches and how they push for prospects will change.

In click-bait headline news...Is Tom Herman the best Texas coach ever?

Pissing excellent. Barking Carnivals Scipio Tex on Hermans hydration chart.

Baker Mayfield was born to be a Sooner.

Texas should be in the top 15 pre-season college football ranking.

This poll is closed.

Here is the original post:

Daily Round Up: Should Texas Be A Top 15 CF Team? - Burnt Orange Nation

CF Industries Holdings, Inc. (CF) is now trading with a very clear set of technicals. Taken together they paint a very compelling picture of how investors and traders should be approaching CF. The technical chart is a rich source of information and traders can get a whole of power from using it correctly.

CFs most recent trading session saw the stock achieve a high of $29.48 and a low of $28.49. The high in the most recent session compares poorly to the established 52-week high of $36.86 which was set by CF on 01/25/17. The recent low represents a +37.79% since 08/04/16 which is a good sign for traders looking to capitalize on the stocks upside. The current trading pattern for the stock is very telling when one looks at the overall sentiment of analysts. Presently there is a target price of $33.35 set for CF, a figure which is below the most recent high set by the stock. The stock also has a beta of 1.25. Since the beta is greater than 1, it can be interpreted that the stock is theoretically more volatile than the market something traders will surely be keeping an eye on.

There are other technical factors that have started to present an impactful picture based on the state of play for the stock. Both the Relative strength indicator (RSI) and Stochastic measures have come into play for CF. Based on current readings for CF, the 14-day RSI is 41.25%. This suggests that CF is neutral, suggesting that the stock is relatively stable in terms of upward or upward price movement. The stochastic reading is also very revealing based on current readings. In this case, CF has a stochastic reading of 41.78%. This suggests CF is neither overbought nor oversold at prevailing levels. CF also paints a compelling picture via its 50 and 200 SMAs. CF, based on the current trend can be considered bullish. This sentiment has created an attitude towards the stock which can be reasonably said to be positive.

Traders can bolster their view of a stocks upside by taking a keen look at other technicals in support of the ones explored above. CFs -0.23 has created a negative sentiment when measured over the past 30 days. CF has underperformed the S&P 500 by -17.25. This, has concluded initially, has created higher volatility levels when compared to other stocks in the same sector. Historical volatility for CF is showing a reading of 36.14%. CF also presents with an Average True Range reading of 3.33. CF and its technical indicators now show a full picture and a very good sense of where traders need to invest their time and energy. These readings should not be ignored.

See the rest here:

CF Industries Holdings, Inc. (CF) Is Now On The Radar Because Of Its Technical Chart - NY Stock News

Cristiano Ronaldo became the first player to score 100 goals in UEFAcompetitions after he helped Real Madrid C.F. beat FCBayern Munich 2-1 in the Champions League quarterfinal clash.

Real Madrids Cristiano Ronaldo may be on course for his worst domestic goal haul since 2010 but with two strikes against Bayern Munich in the Champions League quarter-final first leg on Wednesday he became the first player to score 100 goals in UEFA competitions.

Zinedine Zidanes side drew with neighbours Atletico Madrid in La Liga on Saturday and looked likely to fall short again after being outplayed by Bayern in the first half before Ronaldo came to the rescue to seal a 2-1 win.

When Arturo Vidal headed the hosts into a 25th-minute lead, Bayern appeared on course for a 17th consecutive European home victory, but the game turned following Vidals missed penalty and Ronaldo equalised with a fine volley early in the second period.

Javi Martinezs sending-off just after the hour mark handed Real the initiative, and the 32-year-old Ronaldo clinched Reals victory when he beat Manuel Neuer after being picked out by Marco Asensio in the 77th minute.

While the Portugal forward has demonstrated an ability to win matches single-handedly throughout his career, his latest survival act came in an unfamiliar context having struggled to hit the lofty heights he sets himself in La Liga this season.

Cristiano was unhappy because he couldnt score a third, thats how ambitious he is,Zidane told reporters.

Despite an admirable 19 goals in 24 league appearances, Ronaldo looks unlikely to match the tallies he has managed in his last six seasons (40, 46, 34, 31, 48, 35). And he had previously gone 613 minutes of European football without finding the net - his longest drought for eight years.

Yet he delivered an outstanding second-half performance to reach 100 European goals, with 98 in the Champions League and two coming in Madrids 2-0 UEFA Super Cup victory over Sevilla in 2014.

Of Ronaldos haul in Europes top competition, he has managed 82 for Real, with the other 16 coming for Manchester United, and his double took him four goals ahead of Lionel Messi (94) in the race to become the first player to score 100 Champions League goals.

Real still have to fend off a likely Bayern fightback on Tuesday, but they remain on course to become the first team to retain the Champions League.

At this rate, you would not bet against Ronaldo reaching his century in the competition before the end of this campaign.

Read the original here:

Cristiano Ronaldo slams 100th goal in Real Madrid CF's win in Champions League - Hindustan Times

Subscribe today for full access on your desktop, tablet, and mobile device.

8

Let friends in your social network know what you are reading about

1:10 p.m., Fox Sports Detroit, WXYT-FM (97.1): The top two teams in the AL Central continue their three-game series

Try Another

Audio CAPTCHA

Image CAPTCHA

Help

CancelSend

A link has been sent to your friend's email address.

A link has been posted to your Facebook feed.

In this week's episode, Anthony Fenech sits in the Detroit Tigers' dugout to analyze the Joe Jimenez call-up and more. Subscribe to "Talkin' Tigers" in iTunes or Google Play.

Tigers pitcher Shane Greene (61) checks the runner at first in the seventh inning of the Tigers' 2-1 win Tuesday at Comerica Park.(Photo: Rick Osentoski USA TODAY Sports)

When: 1:10 p.m. today.

Where: Comerica Park, Detroit.

TV: Fox Sports Detroit.

Radio: WXYT-FM (97.1; other radio affiliates).

Weather forecast: Partly cloudy, 53 degrees.

Probable starting pitchers: RHP Michael Fulmer (0-0, 0.00 ERA) vs. RHP Kyle Gibson (0-0, 5.40 ERA).

Tigers lineup:

1. Ian Kinsler, 2B

2. Nick Castellanos, 3B

3. Miguel Cabrera,1B

4. Victor Martinez, DH

5. Justin Upton, LF

6. Tyler Collins, RF

7. James McCann, C

8. Andrew Romine, CF

9. Jose Iglesias, SS

Game notes: The Tigers took Game 1 of this three-game set, 2-1, on Tuesday. ... Detroit must feel good handing the ball to Fulmer. He pitched six scoreless innings in the home opener against the Boston Red Sox on Friday. ... Gibson was 1-1 with a 4.15 ERA and a 1.46 WHIP in two starts against the Tigers last season. ...McCann is the first catcher in Tigers history to hit at least three home runs through the teams first seven games. ... The Tigers have hit at least one home run in each of their first seven games, tyingthe longest such streak to begin a season in franchise history (2014). No AL team has homered in each of their first eightgames since the Cleveland Indians did so in nine straight in 2012.

Twitter updates

On mobile? Tap here for live updates.

Related:

J.D. Martinez takes batting practice for 1st time since injury

Tigers' bullpen continues to live dangerously, gets by late vs. Twins

1:36

1:04

1:25

0:56

1:17

1:26

1:58

2:11

1:43

1:32

0) { %>

0) { %>

See more here:

Tigers' lineup: Romine in CF, Collins RF today - Detroit Free Press

Campaigner Jillian McNulty, who has cystic fibrosis, celebrates the news of the funding with Michel Martin, outside the Dil. Photograph: Brenda Fitzsimons

The Governments decision to fund two new drugs for up to 600 patients with cystic fibrosis was made in the absence of any agreement on the source of funding for the deal.

The Health Service Executive (HSE) has made it clear to Minister for Health Simon Harris and his officials that it cannot afford to fund the deal to provide Orkambi and Kalydeco, according to well-informed sources. It wants the cost to be met from additional funds from Government.

The Minister has refused to disclose the cost of the agreement, but it is believed to be close to 400 million.

Mr Harris told the Dil on Tuesday that agreement had been reached in principle with the manufacturer, Vertex Pharmaceuticals, on reimbursing the cost of the drugs. The deal was reached without the matter being approved by Cabinet, as was expected.

The announcement was welcomed by patients with cystic fibrosis, who called off a demonstration planned outside the Dil for the following day.

The Minister told TDs we are now in the concluding stages of an agreement and predicted the matter would be finalised in the coming days. He said the cost was not being made public as this was commercially sensitive information.

The HSE has previously said, when Vertex was seeking 400 million for Orkambi alone over five years, that it could not afford to pay for the drug. Sources estimate that the company dropped its price by about 40 per cent during negotiations, but the inclusion of Kalydeco and as yet undeveloped drugs in the overall deal means the final cost may be about 400 million.

Responding to queries, the Ministers spokeswoman declined to say whether the deal would be funded by the HSE or from new monies, saying this, too, was commercially sensitive. The agreement was approved by Government, she added, notwithstanding the matter had not yet come to Cabinet. The Department of the Taoiseach and the Department of Public Expenditure were kept apprised.

The HSE is unable to afford the cost of these and other new drugs awaiting approval. The 40 other licensed drugs awaiting a reimbursement decision have a combined potential cost of more than 1 billion.

They include Respreeza, a drug for patients with genetic emphysema, 17 of whom are on a trial that is due to end this month. Muscular Dystrophy Ireland has called on the HSE to approve Translarna, another drug awaiting approval that is the first treatment to address an underlying genetic cause of the condition.

Fianna Fil TD, Marc MacSharry, while welcoming the agreement with Vertex, has expressed concern about the agreement in principle referred to by Mr Harris, and has called for clarification that the rollout of the drug will not be delayed.

Read the rest here:

Decision to fund CF drugs made without funding agreement - Irish Times

Cystic fibrosis patients in Sligo-Leitrim are set to benefit from a new deal between the Health Service Executive and pharmaceutical company, Vertex, which will see Orkambi and Kalydeco made available from next month.

The HSE are now working to finalise the contractual terms to make sure we have the best and most robust deal possible for CF patients and the healthcare service overall.

Sligo-Leitrim TD Tony McLoughlin says that the deal announced by Minister for Health, Simon Harris is a landmark decision for CF patients and their families. The HSE and Vertex have reached an agreement in principle on the commercial terms for the supply to Irish patients of Orkambi for patients aged 12 years an older and for Kalydeco for patients aged 2 to 5 years and for other treatments and age cohorts following market authorisation in Europe.

This is great news for CF patients here in Sligo-Leitrim. I know that this has been a particularly difficult time for all cystic fibrosis patients and their families and hopefully this announcement gives them some degree of relief and certainty.

I want to thank my Fine Gael colleague, the Minister for Health, Simon Harris, and the HSE for bringing this deal to fruition. I know they have been working hard on this deal for a number of months."stu

Speaking of the announcement, Minister Harris said, I was very pleased to be in a position to bring this news to CF patients and their families this week. I hope that it will help to finally put people's minds at rest, knowing that the drugs their family and friends need will be available to them from the beginning of next month.

See more here:

Leitrim welcome for CF drugs - Leitrim Observer

Micro cap Protalix BioTherapeutics (NYSEMKT:PLX) is up8%premarket on robust volume in response to its announcement of positive results from a 16-subject Phase 2 clinical trial evaluating AIR DNase (alidornase alfa) in cystic fibrosis (CF) patients previously treated with Roche's (OTCQX:RHHBY) Pulmozyme (dornase alfa).

Preliminary data showed patients treated with alidornase alfa experienced a clinically meaningful improvement in lung function as measured by the percent increase in percent predicted forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline. Participants also showed a mean absolute increase of 2.8 points in ppFEV1 compared to the measurements taken when patients switched from Pulmozyme to alidornase alfa.

A correlation between sputa parameters and pulmonary function was observed. The sputa DNA content in ~half the patients was analyzed which showed an average reduction of over 70% from baseline. There was more than a 90% reduction from baseline in sputa visco-elasticity.

An in vitro study showed alidornase alfa significantly inhibited the bacterium Pseudomonas aeruginosa, a major cause of lung infection in CF sufferers.

More complete data will be presented at the 40th European Cystic Fibrosis Conference in June.

According to the company,AIR DNaseis a proprietary plant cell-expressed recombinant form of a human enzyme called deoxyribonuclease 1 (DNase 1) that cleaves extracellular DNA and thins the thick mucus that accumulates in the lungs of CF sufferers. It is designed to be more effective than Roche'sPulmozymeby being more resistant to actin inhibition, which restricts DNase I activity.Actinis a protein that plays a role in a wide range of cellular processes.

Original post:

Protalix Bio's AIR DNase shows positive effect in mid-stage CF study; shares ahead 8% premarket - Seeking Alpha

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Protalix BioTherapeutics, Inc. (NYSE: PLX) announced positive results from the Companys phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF). Sixteen patients were enrolled in the study, all of whom completed the study. alidornase alfa is a plant cell-expressed, chemically-modified recombinant DNase enzyme resistant to inhibition by actin, which the Company has specifically designed to enhance the enzymes efficacy in CF patients.

The phase II trial is a 28-day switchover study to evaluate the safety and efficacy of alidornase alfa in CF patients previously treated with Pulmozyme (currently the only commercially available DNase therapy). Participation in the trial was preceded by a two-week washout period from Pulmozyme before treatment with alidornase alfa via inhalation.

The primary efficacy results show that treatment with alidornase alfa resulted in clinically meaningful lung function improvement, as demonstrated by a mean absolute increase in the percent predicted forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline. Moreover, a mean absolute increase in ppFEV1 of 2.8 points was also observed in patients participating in the trial when compared to measurements taken from patients at initiation before the switch from Pulmozyme to alidornase alfa.

A commercially available small molecule CFTR modulator for the treatment of CF has reported a mean absolute increase in ppFEV1 of 2.5 from baseline in its registration clinical study. This score was achieved while 74% of the patients participating in the trial of the CFTR modulator were also treated with the modulator on top of Pulmozyme. While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, alidornase alfa is being developed to treat all CF patients.

Sputa available DNA samples were analyzed for approximately half of the patients. A mean reduction of over 70% in DNA content from baseline was observed, and a mean reduction of over 90% from baseline was observed for sputa visco-elasticity. Correlation between improvement in sputa parameters and pulmonary function was observed.

In addition, an in vitro study of alidornase alfa demonstrated a significant inhibition of Pseudomonas Aeruginosa, with alidornase alfa treated colonies reduced by over 50%, compared to baseline. Pseudomonas, strains of bacteria that are widely found in the environment, are a major cause of lung infections in CF patients. Chronic pulmonary infection is a leading cause of morbidity and mortality in CF patients, despite the aggressive use of antibiotics, and Pseudomonas is the most prevalent organism in the airway colonization of CF patients.

PK analysis performed indicated alidornase alfa is not absorbed into a patients circulatory system, suggesting higher levels of alidornase alfa remains available in the patient's lungs. This provides further support for the potential that alidornase alfa may offer additional efficacy to CF patients.

The above-mentioned material decrease in visco-elasticity and DNA presence in CF patients sputa, coupled with the significant inhibition of Pseudomonas and higher levels of alidornase alfa available in the patients lungs, provides further supportive evidence of improved lung function after treatment with alidornase alfa, as demonstrated by the increase in FEV1.

alidornase alfa was well tolerated with no serious adverse events reported, and all adverse events that occurred during the study were mild and transient in nature.

The efficacy and safety results of alidornase alfa are very encouraging as they demonstrate data that are clinically relevant which brings new hope to CF patients living with this devastating disease, said Professor Eitan Kerem, Chairman of Pediatrics, Head of The Cystic Fibrosis Center, Hadassah University Hospital, and a Principal Investigator in the clinical trial. I look forward to taking part in future clinical studies of alidornase alfa as I believe it has the potential to become a gold standard treatment for all CF patients.

We are very excited with the clinical data showing a significant, clinically meaningful improvement in efficacy, and potentially offering new alternatives to all CF patients, commented Moshe Manor, Protalixs President and Chief Executive Officer. We look forward to exploring different paths for advancing the clinical development of alidornase alfa.

Data from the study was accepted as an oral presentation at the 40th European Cystic Fibrosis Conference to be held in June 2017.

Read the original here:

Protalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF - StreetInsider.com